HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study

Elisabeth Pasquier 1 Luc de Saint-Martin 2, 1 Gisèle Marhic 3 Céline Chauleur 4 Caroline Bohec 5 Florence Bretelle 6 Véronique Lejeune-Saada 7 Jacob Hannigsberg 8 Geneviève Plu-Bureau 9, 10 Virginie Cogulet 8 Philippe Merviel 1 Dominique Mottier 1
1 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
2 DMIP - Brest - Département de Médecine Interne et Pneumologie [Brest]
3 CIC Brest
4 GRT (EA 3065) - Groupe de recherche sur la thrombose
5 PAU - Hop F Mitterand - Hôpital François Mitterand
6 URMITE - Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes
7 Service d'endocrinologie, gynécologie et diabétologie pédiatriques [CHU Necker]
8 University Hospital Brest
9 Service de gynécologie et d'endocrinologie [CHU Cochin]
10 Hôpital Cochin [AP-HP]
Abstract : Recurrent miscarriage (RM), defined by three or more consecutive losses during the first trimester of pregnancy, affects 1%–2% of fertile couples. Standard investigations fail to reveal any apparent cause in ~50% of couples. However, on the basis of animal models and clinical studies, several hypotheses have been put forward concerning underlying mechanisms of RM: altered ovarian reserve, progesterone defect, thrombotic and/or endothelial dysfunction and immunological disturbances. Nonetheless, no study has yet reached conclusive beneficial clinical evidence for a potential treatment in unexplained RM. Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy. The pharmacological properties of HCQ (eg, antithrombotic, vascular protective, immunomodulatory, improved glucose tolerance, lipidlowering and anti-infectious) could be effective against some mechanisms of unexplained RM. Furthermore, eventhough clinical benefit of HCQ is suggested in prevention of thrombotic and late obstetric events in antiphospholipid (APL) syndrome, there are no data suggesting the benefit of HCQ in RM in the presence of APL antibodies.
Document type :
Journal articles
Complete list of metadata

Cited literature [61 references]  Display  Hide  Download
https://hal.univ-brest.fr/hal-02082511
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Wednesday, December 11, 2019 - 3:42:15 PM
Last modification on : Friday, April 1, 2022 - 3:49:29 AM
Long-term archiving on: : Thursday, March 12, 2020 - 9:05:43 PM

File

Vignette du document
e025649.full.pdf
Publisher files allowed on an open archive

Licence

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

UNIV-AMU | UNIV-BREST | UDL | CNRS | GETBO | IBSAM | UNIV-ST-ETIENNE | IRD | INSERM

Citation

Elisabeth Pasquier, Luc de Saint-Martin, Gisèle Marhic, Céline Chauleur, Caroline Bohec, et al.. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. BMJ Open, BMJ Publishing Group, 2019, 9 (3), pp.e025649. ⟨10.1136/bmjopen-2018-025649⟩. ⟨hal-02082511⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

154

Files downloads

66